The prevalence and risk of mortality associated with antimicrobial resistance within nosocomial settings-a global systematic review and meta-analysis of over 20,000 patients.

IF 10 1区 医学 Q1 MEDICINE, GENERAL & INTERNAL
EClinicalMedicine Pub Date : 2025-08-21 eCollection Date: 2025-09-01 DOI:10.1016/j.eclinm.2025.103384
Nisha A George, Daniel Pan, Luisa Silva, Rebecca F Baggaley, Patricia Irizar, Pip Divall, Amani Al-Oraibi, Durdana P Khan, Christopher A Martin, Joshua Nazareth, Ian Collins, See Lek Chew, Laura B Nellums, Manish Pareek
{"title":"The prevalence and risk of mortality associated with antimicrobial resistance within nosocomial settings-a global systematic review and meta-analysis of over 20,000 patients.","authors":"Nisha A George, Daniel Pan, Luisa Silva, Rebecca F Baggaley, Patricia Irizar, Pip Divall, Amani Al-Oraibi, Durdana P Khan, Christopher A Martin, Joshua Nazareth, Ian Collins, See Lek Chew, Laura B Nellums, Manish Pareek","doi":"10.1016/j.eclinm.2025.103384","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Bacterial antimicrobial resistance (AMR) is a leading cause of death globally. However, there has been no data synthesis on whether it influences mortality within hospital settings. We conducted a systematic review and meta-analysis to quantify the prevalence and risk of mortality associated in hospitalised patients with AMR, compared to patients with infections not classified as AMR.</p><p><strong>Methods: </strong>Databases (MEDLINE, EMBASE, and Cochrane library) were searched from inception up to 14th April 2025 for studies that reported the prevalence of AMR in patients who acquired infections in hospitals and mortality (PROSPERO CRD42023420609). We calculated pooled prevalence estimates of AMR as well as unadjusted and adjusted estimates of the effect of AMR on mortality using a random-effects model. Study quality was assessed using the Joanna Briggs Quality Appraisal Tool, risk of bias using DOI plots and LFK index and certainty of evidence of mortality using GRADE criteria.</p><p><strong>Findings: </strong>We identified 34 studies (20,658 patients with resistant organisms) from 18 countries-namely the USA, China, the UK, Canada, Israel, Japan, Malaysia, Korea, Brazil, and Singapore. Of these, 33 were observational studies whilst two studies (one observational study and one purely modelling study) mechanistically modelled risk of mortality in relation to transmission. No studies were conducted in the African subcontinent, the Middle-East, Russia, and India. The prevalence of AMR was high in patients in hospital (pooled prevalence: 36.5%, 95% CI: 29%-44%, <i>I</i> <sup><i>2</i></sup> = 99%) and associated with higher mortality (unadjusted pooled risk ratio [RR]: 1.64, 95% CI: 1.37-1.97, <i>I</i> <sup><i>2</i></sup> = 96.22%, τ<sup>2</sup> = 0.20; adjusted pooled RR: 1.58, 95% CI: 1.33-1.87, <i>I</i> <sup><i>2</i></sup> = 85.9%, τ<sup>2</sup> = 0.13) compared to non-AMR organisms.Sensitivity analyses showed particularly elevated risks for in-hospital mortality and for AMR-associated bacteraemia. Study quality was generally rated to be high, but there was evidence of publication bias in estimates of both prevalence and mortality. Overall certainty of evidence of mortality was graded to be low.</p><p><strong>Interpretation: </strong>AMR is highly prevalent within hospital settings globally and associated with increased in-hospital mortality. Crucially, no data was identified from the India subcontinent, African subcontinent, the Middle East, and Russia, and only two studies used mechanistic modelling to explore how transmission of AMR affects mortality. Further research is required, particularly in underrepresented regions to inform interventions aimed at reducing both AMR transmission and its related mortality within hospital settings.</p><p><strong>Funding: </strong>Pacific Life.</p>","PeriodicalId":11393,"journal":{"name":"EClinicalMedicine","volume":"87 ","pages":"103384"},"PeriodicalIF":10.0000,"publicationDate":"2025-08-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12496217/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"EClinicalMedicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.eclinm.2025.103384","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/9/1 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Bacterial antimicrobial resistance (AMR) is a leading cause of death globally. However, there has been no data synthesis on whether it influences mortality within hospital settings. We conducted a systematic review and meta-analysis to quantify the prevalence and risk of mortality associated in hospitalised patients with AMR, compared to patients with infections not classified as AMR.

Methods: Databases (MEDLINE, EMBASE, and Cochrane library) were searched from inception up to 14th April 2025 for studies that reported the prevalence of AMR in patients who acquired infections in hospitals and mortality (PROSPERO CRD42023420609). We calculated pooled prevalence estimates of AMR as well as unadjusted and adjusted estimates of the effect of AMR on mortality using a random-effects model. Study quality was assessed using the Joanna Briggs Quality Appraisal Tool, risk of bias using DOI plots and LFK index and certainty of evidence of mortality using GRADE criteria.

Findings: We identified 34 studies (20,658 patients with resistant organisms) from 18 countries-namely the USA, China, the UK, Canada, Israel, Japan, Malaysia, Korea, Brazil, and Singapore. Of these, 33 were observational studies whilst two studies (one observational study and one purely modelling study) mechanistically modelled risk of mortality in relation to transmission. No studies were conducted in the African subcontinent, the Middle-East, Russia, and India. The prevalence of AMR was high in patients in hospital (pooled prevalence: 36.5%, 95% CI: 29%-44%, I 2 = 99%) and associated with higher mortality (unadjusted pooled risk ratio [RR]: 1.64, 95% CI: 1.37-1.97, I 2 = 96.22%, τ2 = 0.20; adjusted pooled RR: 1.58, 95% CI: 1.33-1.87, I 2 = 85.9%, τ2 = 0.13) compared to non-AMR organisms.Sensitivity analyses showed particularly elevated risks for in-hospital mortality and for AMR-associated bacteraemia. Study quality was generally rated to be high, but there was evidence of publication bias in estimates of both prevalence and mortality. Overall certainty of evidence of mortality was graded to be low.

Interpretation: AMR is highly prevalent within hospital settings globally and associated with increased in-hospital mortality. Crucially, no data was identified from the India subcontinent, African subcontinent, the Middle East, and Russia, and only two studies used mechanistic modelling to explore how transmission of AMR affects mortality. Further research is required, particularly in underrepresented regions to inform interventions aimed at reducing both AMR transmission and its related mortality within hospital settings.

Funding: Pacific Life.

医院环境中与抗菌素耐药性相关的流行率和死亡风险——一项针对2万多名患者的全球系统综述和荟萃分析
背景:细菌抗微生物药物耐药性(AMR)是全球死亡的主要原因。然而,目前还没有关于它是否影响医院内死亡率的综合数据。我们进行了一项系统回顾和荟萃分析,以量化AMR住院患者与未归类为AMR的感染患者的患病率和死亡风险。方法:检索数据库(MEDLINE、EMBASE和Cochrane图书馆),从成立到2025年4月14日,检索报告在医院获得性感染患者中AMR患病率和死亡率的研究(PROSPERO CRD42023420609)。我们使用随机效应模型计算了AMR的合并患病率估计值,以及AMR对死亡率影响的未调整和调整估计值。使用Joanna Briggs质量评估工具评估研究质量,使用DOI图和LFK指数评估偏倚风险,使用GRADE标准评估死亡率证据的确定性。研究结果:我们从18个国家(即美国、中国、英国、加拿大、以色列、日本、马来西亚、韩国、巴西和新加坡)鉴定了34项研究(20,658例耐药菌患者)。其中,33项是观察性研究,而两项研究(一项观察性研究和一项纯粹的建模研究)机械地模拟了与传播有关的死亡风险。没有在非洲次大陆、中东、俄罗斯和印度进行研究。住院患者AMR患病率较高(合并患病率:36.5%,95% CI: 29%-44%, i2 = 99%),与非AMR患者相比,AMR死亡率较高(未调整合并风险比[RR]: 1.64, 95% CI: 1.37-1.97, i2 = 96.22%, τ2 = 0.20;调整合并风险比:1.58,95% CI: 1.33-1.87, i2 = 85.9%, τ2 = 0.13)。敏感性分析显示,住院死亡率和抗菌素耐药性相关菌血症的风险特别高。研究质量通常被评为高,但有证据表明,在估计患病率和死亡率方面存在发表偏倚。死亡率证据的总体确定性被分级为低。解释:抗菌素耐药性在全球医院环境中非常普遍,并与院内死亡率增加有关。关键是,没有发现来自印度次大陆、非洲次大陆、中东和俄罗斯的数据,只有两项研究使用了机制模型来探索抗菌素耐药性的传播如何影响死亡率。需要进一步的研究,特别是在代表性不足的地区,为旨在减少抗菌素耐药性传播及其在医院环境中的相关死亡率的干预措施提供信息。资金来源:太平洋人寿。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
EClinicalMedicine
EClinicalMedicine Medicine-Medicine (all)
CiteScore
18.90
自引率
1.30%
发文量
506
审稿时长
22 days
期刊介绍: eClinicalMedicine is a gold open-access clinical journal designed to support frontline health professionals in addressing the complex and rapid health transitions affecting societies globally. The journal aims to assist practitioners in overcoming healthcare challenges across diverse communities, spanning diagnosis, treatment, prevention, and health promotion. Integrating disciplines from various specialties and life stages, it seeks to enhance health systems as fundamental institutions within societies. With a forward-thinking approach, eClinicalMedicine aims to redefine the future of healthcare.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信